<DOC>
	<DOCNO>NCT00299936</DOCNO>
	<brief_summary>The purpose study compare PEG-interferon alfa-2b two different dos rivavirin treatment chronic hepatitis C previously untreated adult subject</brief_summary>
	<brief_title>Comparison PEG-Intron Two Different Doses Ribavirin Treatment Chronic Hepatitis C In Treatment Na√Øve Subjects</brief_title>
	<detailed_description>Primary Objective : This study evaluate safety efficacy two different PEG-interferon Ribavirin regimens patient previously treat Hepatitis C. Patients equal chance assignment one two treatment arm : Treatment Arm A : PEG-interferon 1.5 mcg/kg2 QW + Ribavirin 800 mg/day OR Treatment Arm B : PEG-interferon 1.5mcg/kg2 QW + Ribavirin 800 1400 mg/day Arm A &amp; Arm B : Duration treatment 48 week genotype 1 patient 24 48 week genotype 2 3 patient .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Adult naive subject diagnosis compensate chronic hepatitis C ( HCV RNA+ ) previously treat interferon , PEGinterferon , ribavirin , combination interferon + ribavirin select study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2006</verification_date>
	<keyword>hepatitis C</keyword>
	<keyword>chronic hepatitis C</keyword>
	<keyword>ribavirin</keyword>
	<keyword>WIN-R</keyword>
</DOC>